Abstract
The availability of large collections of small-molecule inhibitors of protein interactions would bear a tremendous impact both on academic and therapeutic research. The past recent years have seen a marked acceleration in the discovery of protein interaction inhibitors, through structure-based drug design but mostly through screening efforts. This article attempts to review the impressive number and variety of in vitro and cellular screening assays that have been developed and, for most of them, used successfully to identify smallmolecule inhibitors of protein interactions. Various strategies aimed at improving hit rates are also reviewed, and future challenges to improve discovery success rates are discussed. The growing list of protein interaction inhibitors and the large arsenal of screening methods, now available to most laboratories or screening facilities, will probably convince an increasing number of academic and industrial scientists that protein interactions are more druggable than once feared, and that their respective research interests would greatly benefit from the discovery of protein interaction inhibitors.
Keywords: High-throughput screening, protein interactions, drug discovery, two-hybrid
Current Drug Discovery Technologies
Title: High-Throughput Screening Assays to Discover Small-Molecule Inhibitors of Protein Interactions
Volume: 5 Issue: 3
Author(s): Pierre Colas
Affiliation:
Keywords: High-throughput screening, protein interactions, drug discovery, two-hybrid
Abstract: The availability of large collections of small-molecule inhibitors of protein interactions would bear a tremendous impact both on academic and therapeutic research. The past recent years have seen a marked acceleration in the discovery of protein interaction inhibitors, through structure-based drug design but mostly through screening efforts. This article attempts to review the impressive number and variety of in vitro and cellular screening assays that have been developed and, for most of them, used successfully to identify smallmolecule inhibitors of protein interactions. Various strategies aimed at improving hit rates are also reviewed, and future challenges to improve discovery success rates are discussed. The growing list of protein interaction inhibitors and the large arsenal of screening methods, now available to most laboratories or screening facilities, will probably convince an increasing number of academic and industrial scientists that protein interactions are more druggable than once feared, and that their respective research interests would greatly benefit from the discovery of protein interaction inhibitors.
Export Options
About this article
Cite this article as:
Colas Pierre, High-Throughput Screening Assays to Discover Small-Molecule Inhibitors of Protein Interactions, Current Drug Discovery Technologies 2008; 5 (3) . https://dx.doi.org/10.2174/157016308785739875
DOI https://dx.doi.org/10.2174/157016308785739875 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chlorinated Paraffins in Indoor Dust Samples: A Review
Current Organic Chemistry Alkannins and Shikonins: A New Class of Wound Healing Agents
Current Medicinal Chemistry Characterization and Antihypertensive Effect of the Complex of (-)-β- pinene in β-cyclodextrin
Current Pharmaceutical Biotechnology Novel Spiro/non-Spiro Pyranopyrazoles: Eco-Friendly Synthesis, In-vitro Anticancer Activity, DNA Binding, and In-silico Docking Studies
Current Bioactive Compounds Melamine Derivatives - A Review on Synthesis and Application
Current Organic Synthesis Opportunities for Nano-Formulations in Type 2 Diabetes Mellitus Treatments
Current Pharmaceutical Biotechnology Oleic Acid Protects Against Oxidative Stress Exacerbated by Cytarabine and Doxorubicin in Rat Brain
Anti-Cancer Agents in Medicinal Chemistry Mechanisms Involved in the Anti-Inflammatory Properties of Native and Genetically Engineered Lactic Acid Bacteria
Anti-Infective Agents Meet Our Editorial Board Member:
Current Nanoscience Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma
Anti-Cancer Agents in Medicinal Chemistry Cunninghamella Biotransformation - Similarities to Human Drug Metabolism and Its Relevance for the Drug Discovery Process
Current Drug Metabolism HR-MAS NMR Spectroscopy: A Practical Guide for Natural Samples
Current Organic Chemistry Antithrombin, an Important Inhibitor in Blood Clots
Current Topics in Medicinal Chemistry Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design UV Sunscreens of Microbial Origin: Mycosporines and Mycosporine- like Aminoacids
Recent Patents on Biotechnology Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection
Current Pharmaceutical Design Elucidation of Cellular Metabolism Via Metabolomics and Stable-Isotope Assisted Metabolomics
Current Pharmaceutical Biotechnology A Water-Soluble Fenbendazole (FBZ) Formulation for Treating Pinworm Infections in Laboratory Animals
Drug Delivery Letters Clinical Review of COVID-19; Pathogenesis, Diagnosis, and Management
Current Pharmaceutical Design High-dose Cholecalciferol Supplementation Reducing Morning Blood Pressure in Normotensive DM1 Patients
Current Diabetes Reviews